拉米夫定联合干扰素治疗慢性乙型肝炎的疗效观察

目的:观察拉米夫定与干扰素联合用药治疗慢性乙肝的疗效。方法:将150例慢性乙肝患者随机分为三组,每组50例。联合组予拉米夫定和重组人干扰素α-2b治疗,拉米夫定组单予拉米夫定治疗;干扰素组单予干扰素治疗,疗程均为1年。结果:治疗1年后,联合组HBV-DNA转阴率为86%,血清HBeAg/抗HBe转换率为48%,均优于拉米夫定组和干扰素组(P<0.05)。联合组仅出现1例YMDD变异(2%),而拉米夫定组出现8例YMDD变异(16%)。结论:拉米夫定联合干扰素应用的治疗效果优于单独应用组,并且能减少病毒YMDD变异,防止耐药发生。

Observation of combination of lamivudine and interferon in the treatment of patients with chronic hepatitis B

Objective To observe the effect of combination of lamivudine and interferon in the treatment of patients with chronic hepatitis B.Methods 150 patients with chronic hepatitis B were divided into 3 groups,each group had 50 patients.The patients in combination group received lamivudine and interferonα-2b therapy for one year,the patients in lamivudine group and interferon group received lamivudine and interferonα-2b therapy respectively for one year.Results After one year,the HBV DNA loss and HBeAg/anti-HBe seroconversion in combination group were 86% and 48% respectively,they were higher than in lamivudine group and interferon group（P0.05）,YMDD mutations were detected in 1 patients in combination group（2%） but 8 patients in lamivudine group（16%）.Conclusion Combination of lamivudine and interferon in the treatment of patients with chronic hepatitis B get a better effect and decrease YMDD mutation.